TECTA

Across TCGA pan-cancer cohorts, TECTA RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of TECTA’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where TECTA RNA is repressed in tumor relative to normal tissue. In most cancer types TECTA is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LUSC, and LUAD are the cancer types where TECTA tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TECTA RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.848	<.001	11	view →
LUSC	Male	II,III,IV	−0.453	<.001	7	view →
LUAD	Female	II,III,IV	−0.435	<.001	6	view →
KIRP	Male	All	−0.324	<.001	6	view →
KIRC	Male	III,IV	−0.181	.002	6	view →
UCEC	All	IV	−0.464	<.001	4	view →
READ	All	All	−0.203	.025	4	view →
BLCA	Male	IV	−0.357	.012	2	view →
STAD	All	All	−0.162	.022	2	view →
COAD	Male	All	−0.123	.023	2	view →
LIHC	Male	II,III,IV	−0.375	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

TECTA–THCA

Open the THCA breakdown →